Menu

Another Andrew Wakefield Movie in the Works

This one will be largely based on the discredited anti-vaccine researcher’s 2010 book.

May 4, 2016
Bob Grant

YOUTUBE, THE WELLNESS WAY CLINICSIt looks like notorious anti-vaccine researcher Andrew Wakefield will make it onto the silver screen yet again. A month ago, the documentary he co-directed, Vaxxed, premiered in New York City. Now, a Hollywood screenwriter—with cowriting credits on blockbusters including Shrek and Pirates of the Caribbean—intends to write a film adaptation of Wakefield’s 2010 book Callous Disregard: Autism and Vaccines—The Truth Behind a Tragedy.

By all appearances, the new film will be a sympathetic look at the life and work of Wakefield, whose claims that measles, mumps, and rubella (MMR) vaccines cause autism have been thoroughly debunked by reams of scientific research. Wakefield himself was repudiated by publishers and the U.K.’s General Medical Council for violating ethical standards. Similarly, the claims Wakefield made in Callous Disregard have been disproven. “[The book] is just terrible,” Joel Harrison, a retired epidemiologist who wrote a point-by-point takedown of Wakefield’s book in a 2013 The Open Vaccine Journal article, told STAT News. “If he handed it in as a term paper as an undergraduate, I wouldn’t pass him.”

Terry Rossio, the screenwriter taking on the new Wakefield movie project, has indicated that the film will highlight the work and life of the controversial researcher. “Dr. Wakefield is clearly a polarizing figure, reviled by the general public yet also revered by many,” he told Variety. “The details and drama surrounding his life are even more remarkable than generally known.”

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing
Bio-Rad Introduces Isotype-Specific Secondary Antibodies
Bio-Rad Introduces Isotype-Specific Secondary Antibodies
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its isotype-specific secondary antibodies. This new range of recombinant monoclonal antibodies, directed against the three main mouse isotypes: IgG1, IgG2a, and IgG2b, offer improved signal detection and specificity in imaging, ELISA, flow cytometry, and western blotting.